Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures [version 1; peer review: 3 approved]

Peter J. Neumann, Jordan E. Anderson, Ari D. Panzer, Elle F. Pope, Brittany N. D'Cruz, David D. Kim, Joshua T. Cohen

Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

Abstract

**Background:** We examined the similarities and differences between studies using two common metrics used in cost-effectiveness analyses (CEAs): cost per quality-adjusted life years (QALYs) gained and cost per disability-adjusted life year (DALY) averted.

**Methods:** We used the Tufts Medical Center CEA Registry, which contains English-language cost-per-QALY gained studies, and Global Cost-Effectiveness Analysis (GHCEA) Registry, which contains cost-per-DALY averted studies. We examined study characteristics including intervention type, sponsor, country, and primary disease, and also analysed the number of CEAs versus disease burden estimates for major diseases and conditions across three geographic regions.

**Results:** We identified 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 and observed rapid growth in publication rates for both literatures. Cost-per-QALY studies were most likely to examine pharmaceuticals and interventions in high-income countries. Cost-per-DALY studies predominantly focused on infectious disease interventions and interventions in low and lower-middle income countries. We found discrepancies in the number of published CEAs for certain diseases and conditions in certain regions, suggesting "under-studied" areas (e.g., cardiovascular disease in Southeast Asia, East Asia, and Oceania and "overstudied" areas (e.g., HIV in Sub Saharan Africa) relative to disease burden in those regions.

**Conclusions:** The number of cost-per QALY and cost-per-DALY analyses has grown rapidly with applications to diverse interventions and diseases. Discrepancies between the number of published studies and disease burden suggest funding opportunities for future cost-effectiveness research.

**Keywords**
Quality-adjusted life years, Disability-adjusted life years, Cost-effectiveness
### Introduction

Researchers conducting cost-effectiveness analyses (CEAs) commonly use quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs) as health outcome measures to account for both longevity and quality of life (or life with disability)\(^1\). These broadly applicable metrics facilitate comparisons across conditions and diseases.

Analysts have used these measures in different contexts and settings\(^2–6\). CEAs using the cost-per-QALY metric, which first appeared in the late 1970s, have typically focused on interventions in higher incomes settings\(^2–4\). In the 1990s, the World Bank and the World Health Organization (WHO) developed the DALY to quantify disease burden (reflecting both years of life lost (YLL) and years of life with disability (YLD))\(^5–10\). CEAs using DALYs have tended to focus on lower- and middle-income countries\(^11\).

QALYs and DALYs, which both quantify health related quality of life by assigning a value ranging from zero to one to each year with a health condition, have somewhat different methodological underpinnings\(^12\). QALY preference weights range from 0 (corresponding to “dead”) to 1 (corresponding to a hypothetical state of “perfect health”) and reflect a set of health state “attributes”, “dimensions”, or “domains” – e.g., discomfort, mobility, depression, etc. – associated with an individual’s health condition or conditions. DALY weights have a similar intuitive interpretation, although in the case of DALYs, 1 corresponds to “dead” and 0 corresponds to “perfect health. For DALYs, however, each weight corresponds not to a set of health state attributes but to a specific disease\(^13\).

DALY calculations have in the past depended on the age of the affected populations. “Age-weighting” reflected the contention that an additional life year accrued during childhood or old age is worth less than a year accrued during young and middle adulthood, when productivity contributions to societal well-being are typically greatest\(^14,15\). Because the unequal treatment of different age groups raised substantial ethical concerns, the most recent DALY calculation methods have no age-weighting\(^16\).

We analysed the cost-per-QALY gained and cost-per-DALY averted literatures to examine their growth and regional variation, and to analyze the extent to which the focus of each literature corresponded to those diseases and conditions imposing the largest burden on the population.

### Methods

#### Data

**The cost-effectiveness analysis literature.** We analyzed two databases maintained by the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center in Boston, Massachusetts: the Cost-Effectiveness Analysis (CEA) Registry (www.cearegistry.org), which contains information on cost-per-QALY studies, and the Global Health CEA Registry (www.ghcearegistry.org), which houses information on cost-per-DALY studies. Both registries contain information on PubMed-indexed, English-language CEAs published through 2016. Previous publications further detail the search strategies, data collection processes, and review methods, which are similar for both registries\(^15\). We received ethics exemption for this study because it did not involve human subjects. Data from these registries used in this analysis appear in Dataset 1 and Dataset 2; Supplemental file 1 and Supplemental file 2 contain documentation for the variables in these datasets.

**Disease burden.** Dataset 3 contains population disease burden estimates (total DALYs incurred) reported by the Institute for Health Metrics and Evaluation (IHME) stratified by Global Burden of Disease (GBD) Super Region\(^17\). Within each Super Region, we stratified population burden by GBD level into two disease category. Dataset 3 also lists the number of articles from the cost-per-QALY literature and from the cost-per-DALY literature for each of these strata and substrata. Articles focusing on multiple countries could be counted in more than one of the Table 3 strata – e.g., if two countries of focus for a particular study belong to two distinct GBD Super Regions.

**Analysis of data.**

**Study characteristics.** Using data from Dataset 1 and Dataset 2 and definitions from the World Bank and the GBD initiative, we stratified studies by: GBD Super Region, World Bank Income Level, Intervention type, Study Funder category, Prevention stage, and GBD Category. As detailed in Table 1, some of these categories are mutually exclusive, while others are not. We computed the proportion of studies in each stratum using total article counts for the cost-per-QALY and cost-per-DALY literature from Dataset 1 and Dataset 2, respectively.

Based on these counts and proportions, we report the proportion of studies in each stratum (Table 1), number of cost-per-QALY and cost-per-DALY studies published by year (Figure 1), proportion of published CEAs stratified by World Bank country income category and by study type (cost-per-QALY or cost-per-DALY) (Figure 2), and number of cost-per-QALY and cost-per-DALY studies focusing on each country (Figures 3A and 3B).

**Literature coverage vs. disease burden.** We characterized the relationship between the number of CEA studies (cost-per-QALY plus cost-per-DALY) focusing on each disease and corresponding normalized burden for each of three GBD Super Regions: Southeast Asia, East Asia, and Oceania; high-income countries; and Sub-Saharan Africa. We limited attention to the top 10 diseases by total population DALY burden for each of these regions. We computed normalized disease burden as total DALYs attributed to each disease in a Super Region divided by that Super Region’s population. Finally, we identified “under-studied” diseases in each Super Region – i.e., diseases with a normalized burden in excess of the average for other diseases with the same coverage in the literature.

Each figure panel includes a diagonal line that represents the average disease burden as a function of the number...
Table 1. Characteristics of published CEAs using cost-per-QALY and cost-per-DALY through 2016. Countries are classified on 2016 USD into the following categories: low-income (GNI/Capita < $1,005), lower-middle income (GNI $1,006 – $3,955), upper-middle income (GNI $3,956 – $12,235), and high-income (GNI > $12,235)\(^7\). GBD Super regions are as reported in the GBD study, 2010.

|                                | Cost-per-QALY studies | Cost-per-DALY studies | Overall |
|--------------------------------|-----------------------|-----------------------|---------|
| **Number of studies**          | 6438                  | 543                   | 6981    |
| **GBD Super Region**           |                       |                       |         |
| High income                    | 89%                   | 20%                   | 84%     |
| Southeast Asia, East Asia, and Oceania | 4%                     | 11%                   | 5%      |
| Sub-Saharan Africa             | 1%                    | 30%                   | 4%      |
| Multiple Regions#              | 1%                    | 16%                   | 1%      |
| Latin America and Caribbean    | 1%                    | 8%                    | 2%      |
| Central Europe, Eastern Europe, and Central Asia | 1%                             | 2%                    | 1%      |
| South Asia                     | 0%                    | 8%                    | 1%      |
| North Africa and Middle East   | 1%                    | 2%                    | 1%      |
| NA                             | 2%                    | 3%                    | 2%      |
| **World Bank Income Category** |                       |                       |         |
| Low-Income and Lower-Middle-Income | 1%                     | 43%                   | 4%      |
| Upper Middle-Income and High-Income | 97%                   | 37%                   | 92%     |
| Both                           | 0%                    | 17%                   | 2%      |
| None                           | 2%                    | 3%                    | 2%      |
| **Intervention\(^a\)**        |                       |                       |         |
| Pharmaceutical                 | 44%                   | 32%                   | 43%     |
| Surgical                       | 13%                   | 8%                    | 13%     |
| Screening                      | 12%                   | 14%                   | 12%     |
| Care delivery                  | 11%                   | 17%                   | 11%     |
| Medical procedure              | 12%                   | 4%                    | 12%     |
| Health education or behavior   | 9%                    | 21%                   | 10%     |
| Immunization                   | 6%                    | 27%                   | 8%      |
| Other                          | 5%                    | 46%                   | 22%     |
| **Study funder\(^b\)**        |                       |                       |         |
| Government                     | 33%                   | 47%                   | 34%     |
| Pharmaceutical or device company | 29%                   | 4%                    | 27%     |
| Foundation                     | 10%                   | 33%                   | 11%     |
| Healthcare organization\(^\sim\) | 4%                     | 9%                    | 5%      |
| None/Not determined            | 24%                   | 24%                   | 24%     |
| Other                          | 8%                    | 21%                   | 9%      |
Table 1. Published cost-per-QALY and cost-per-DALY studies by prevention stage and GBD category.

| Prevention stage* | Cost-per-QALY studies | Cost-per-DALY studies | Overall |
|-------------------|-----------------------|-----------------------|---------|
| Primary           | 15%                   | 59%                   | 18%     |
| Secondary         | 16%                   | 20%                   | 16%     |
| Tertiary          | 62%                   | 38%                   | 60%     |

| GBD Category                                               | Cost-per-QALY studies | Cost-per-DALY studies | Overall |
|------------------------------------------------------------|-----------------------|-----------------------|---------|
| Neoplasms                                                  | 18%                   | 3%                    | 17%     |
| Cardiovascular and circulatory diseases                    | 17%                   | 5%                    | 16%     |
| Diabetes, urogenital, blood, and endocrine diseases        | 12%                   | 5%                    | 11%     |
| Other communicable, maternal, neonatal, and nutritional disorders | 10%                   | 7%                    | 9%      |
| Musculoskeletal disorders                                 | 10%                   | 1%                    | 9%      |
| Mental and behavioral disorders                            | 6%                    | 7%                    | 6%      |
| HIV/AIDS and tuberculosis                                 | 4%                    | 20%                   | 6%      |
| Digestive diseases                                         | 4%                    | 1%                    | 4%      |
| Diarrhea, LRI, and other common infectious diseases        | 2%                    | 20%                   | 3%      |
| Other                                                      | 18%                   | 31%                   | 19%     |

Key:
*“Multiple regions” refers to studies that reported cost-effectiveness estimates for countries in different regions.
*Health care organizations include insurance companies, hospitals, HMOs, WHO.
*Not mutually exclusive
GBD: Global burden of disease
GNI: Gross National Income
HMO: Health maintenance organization
LRI: Lower respiratory infection
WHO: World Health Organization

Figure 1. Published cost-per-DALY and cost-per-QALY studies by year. Journals published 360 cost-per-QALY studies during the years 1976 through 2000. Journals published 13 cost-per-DALY studies during the years 1995 through 2000.
Figure 2. Cost-per-QALY vs. cost-per-DALY studies by world bank income level. The area of each pie chart is proportional to the number of studies catalogued in each registry.

Figure 3. Number of published cost-per-QALY (3A) and cost-per-DALY (3B) studies by country. The maps present the number of cost-per-QALY and cost-per-DALY studies for each country. Gray countries did not have any studies associated with them. If a study reported a cost-effectiveness estimate for two or more countries, we counted a CEA for each country (e.g. if a study reviewed an intervention in both Canada and the United States, both countries were counted for that study). If a study reported a “global” cost-effectiveness ratio, we excluded it from the counts used to produce this map. We also excluded from these counts studies that did not clearly specify an applicable country or region. (3A) We excluded one study classified as “international”. We excluded 144 studies because the country of study was unclear. (3B) We excluded 13 studies classified as “international”. We excluded 16 studies because the country of study was unclear.
Figure 4. Number of CEAs vs. normalized disease burden for selected diseases and GBD Super Regions. The figures show the relationship between literature coverage (number of cost-per-QALY plus cost-per-DALY studies) focusing on each disease (horizontal axis) and corresponding normalized disease burden (vertical axis) for each of three GBD Super Regions: (4A) Southeast Asia, East Asia, and Oceania; (4B) high-income countries; and (4C) Sub-Saharan Africa. Each panel displays results for the top 10 diseases by total population DALY burden in that region. Normalized disease burden on the vertical axis is the total number of DALYs attributed to each disease in that panel's Super Region divided by the Super Region's population. Each figure panel includes a diagonal line representing average disease burden as a function of literature coverage (total published CEAs). Each disease plotted above this line is “understudied” because its burden is higher, on average, than the corresponding burden for other diseases receiving the same level literature coverage.

of CEA studies (Figures 4A–C). Diseases plotted to the “northwest” of this line are “understudied” within that region because the disease-burden is higher, on average, for that disease than it is for other diseases receiving the same level of attention in the literature.

Results
We identified 6,438 cost-per-QALY (Dataset 1) and 543 cost-per-DALY (Dataset 2) studies published up to 2016. The number of published studies in the cost-per-QALY and cost-per-DALY literatures has increased steadily since 2000 (Figure 1).

Study characteristics
Cost-per-QALY studies have tended to focus on upper-middle income and high-income countries (97%); e.g. United States has 2,321 and United Kingdom 1,149. Cost-per-DALY studies have focused to a much greater extent on low and lower-middle income countries (43%); e.g. India has 95, China has 51, and Uganda has 90 (Table 1, Figure 2, Figure 3A and 3B).

Tertiary prevention (treatment) dominated the cost-per-QALY registry (e.g. pharmaceuticals, 44%; surgery, 13%), whereas the cost-per-DALY registry focused far more on primary prevention (e.g. immunizations, 27%). Conditions most frequently addressed by studies in the cost-per-QALY literature included non-communicable diseases, such as cancer (18%) and cardiovascular diseases (17%), whereas most cost-per-DALY registry studies targeted infectious diseases.

Non-governmental cost-per-DALY study funding came most often from foundations (33%), while cost-per-QALY study funding derived most often from pharmaceutical or device companies (29%).

Literature coverage vs. disease burden
Neoplasms were the most studied diseases in Southeast Asia, East Asia, and Oceania (Figure 4A), while mental and behavioral disorders were less studied relative to their burden. High-income countries (Figure 4B) had relatively few studies addressing mental and behavioral disorders, and injuries.
Relative to burden, HIV/AIDS and tuberculosis were the most studied diseases in Sub-Saharan Africa, while this region reported fewer studies on nutritional deficiencies (Figure 4C).

**Discussion**

Our review reveals a notable increase in the publication of cost-per-QALY and cost-per-DALY studies since 2000, thus making ever more cost-effectiveness information available to aid decision makers in their efforts to prioritize resources. The literature spans a wide range of interventions, diseases, and geographic regions.

The data demonstrate key differences between the cost-per-QALY and cost-per-DALY literatures (Table 1). The cost-per-QALY literature focuses on high-income countries, while cost-per-DALY studies focus more on lower- and middle-income income nations. This contrast seems to reflect the historic proclivities of health economist researchers, rather than any inherent advantages for one metric’s use for a particular category of countries. The differences extend to the types of interventions and diseases represented: cost-per-QALY studies tend to address diseases of wealthier countries (e.g., cardiovascular disease and cancer), while cost-per-DALY studies address diseases more prevalent in low-income countries (e.g., infectious diseases, such as tuberculosis and HIV). The two literatures also differ in terms of the interventions on which they focus. More cost-per-QALY studies evaluate pharmaceuticals, while cost-per-DALY studies focus more often on immunizations.

The most commonly studied diseases, regions, and interventions may reflect the financial interests of the CEA funders. For instance, pharmaceutical companies invest in pharmaceutical CEAs in high-income countries.

Our data also indicate discrepancies between literature coverage and burden of disease. These analyses suggest that some diseases and conditions (e.g., cardiovascular disease and mental health in Southeast Asia, South Asia and Oceania) are “understudied,” while other diseases and conditions (e.g., HIV in Sub-Saharan Africa) are “overstudied”. These discrepancies may represent opportunities for the re-direction of CEA research funding in the future.

**Data availability**

We have made the data used in this analysis available through the Open Science Foundation (OSF): http://doi.org/10.17605/OSF.IO/3BEK59.

License: CC0 1.0 Universal.

**Dataset 1. Cost-per-QALY dataset.**

Includes the cost-per-QALY data used in this paper.

**Dataset 2. Cost-per-DALY dataset.**

Includes the cost-per-DALY data used in this paper.

**Dataset 3. Regional and disease level stratification dataset.**

Includes disease burden and literature coverage data used in this paper.

**Competing interests**

All authors have completed the Unified Competing Interest form and declare: a grant from the Bill and Melinda Gates Foundation for the submitted work; no financial relationships with any organizations that might have interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.

**Grant information**

Bill and Melinda Gates Foundation [OPP1171680].

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Supplementary Material**

**Supplementary File 1. Cost-per-QALY manual.** Documents the variables collected in the cost-per-QALY database.

Click here to access the data.

**Supplementary File 2. Cost-per-DALY manual.** Documents the variables collected in the cost-per-DALY database.

Click here to access the data.
References

1. Neumann PJ, Sanders GD, Russell LB, et al.: Cost-Effectiveness in Health and Medicine. 2nd Edition. New York, NY: Oxford University Press; 2016. Reference Source
2. Airoldi M, Morton A: Adjusting life for quality or disability: stylistic difference or substantial dispute? Health Econ. 2009; 18(11): 1237–1247. PubMed Abstract | Publisher Full Text
3. Teerawattananon Y, Tantivess S, Yamabhai I, et al.: The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh. Health Res Policy Syst. 2016; 14(1): 86. PubMed Abstract | Publisher Full Text | Free Full Text
4. Hutubessy R, Chisholm D, Edejer TT: Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc. 2003; 1(1): 8. PubMed Abstract | Publisher Full Text | Free Full Text
5. Neumann PJ, Thorat T, Zhong Y, et al.: A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. PLoS One. 2016; 11(12): e0168612. PubMed Abstract | Publisher Full Text | Free Full Text
6. Neumann PJ, Thorat T, Shi J, et al.: The changing face of the cost-utility literature, 1990-2012. Value Health. 2015; 18(2): 271–277. PubMed Abstract | Publisher Full Text
7. Gold MR, Siegel JE, Russell LB, et al.: Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996. Reference Source
8. Drummond MF, Sculpher MJ, Torrance GW, et al.: Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford, UK: Oxford University Press; 2014. Reference Source
9. World Bank: World Development Report 1993; Investing in Health. New York: Oxford University Press, 1993. Reference Source
10. Murray CJ, Salomon JA, Mathers CD, et al.: Summary measures of population health: concepts, ethics, measurement and applications. Geneva, 2002. Reference Source
11. Devleesschauwer B, Havelaar AH, Maertens de Noordhout C, et al.: DALY calculation in practice: a stepwise approach. Int J Public Health. 2014; 59(3): 571–574. PubMed Abstract | Publisher Full Text
12. Sassi F: Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 2006; 21(5): 402–408. PubMed Abstract | Publisher Full Text
13. Gold MR, Stevenson D, Fryback DG: HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health. Annu Rev Public Health. 2002; 23: 115–134. PubMed Abstract | Publisher Full Text
14. Amesen T, Nord E: The value of DALY life: problems with ethics and validity of disability adjusted life years. BMJ. 1999; 319(7222): 1423–1425. PubMed Abstract | Publisher Full Text | Free Full Text
15. Robberstad B: QALYs vs DALYs vs LYs gained: what are the differences, and what difference do they make for health care priority setting? Norsk Epidemiologi. 2005; 15(2): 183–191. Publisher Full Text
16. Murray CJ, Ezzati M, Flaxman AD, et al.: GBD 2010: design, definitions, and metrics. Lancet. 2012; 380(9859): 2063–2066. PubMed Abstract | Publisher Full Text
17. Institute for Health Metrics and Evaluation. 2017. Reference Source
18. World Bank Country and Lending Groups. 2017. Reference Source
19. Neumann P: A comparison of cost-effectiveness analyses reporting cost-per-QALYs gained and cost-per-DALYs averted. 2018. Data Source
Open Peer Review

Current Peer Review Status:  ✔  ✔  ✔

Version 1

Reviewer Report 05 February 2018

https://doi.org/10.21956/gatesopenres.13846.r26225

© 2018 Nugent R. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Rachel Nugent
1 RTI International, Seattle, WA, USA
2 Department of Global Health, University of Washington, Seattle, WA, USA

The authors have provided a useful summary of the up-to-date contents of the Tufts Medical Center CEA Registry and Global Health CEA Registry, which they manage. In particular, they contrast the contents of the two databases in regard to number of studies, geographic, disease burden, and disease-specific content. This provides a useful - if somewhat simplistic - overview of the availability and contents of current CEA studies. A few comments regarding the results as presented are provided below, along with a few suggestions about additional ways to interrogate the databases.

1. I am interested to see the time series of cost per QALY and cost per DALY studies presented in Figure 1. There is nothing especially surprising here for anyone working in the field, and it is heartening to see the steady increase in economic evaluations for health. I would appreciate the authors highlighting a few aspects of the databases that help one interpret the data. The methods clearly state that the databases draw from English-language articles indexed in PubMed, but it would be worth underscoring that selection creates a downward bias on the true number of cost per DALY studies. It would be very interesting to know if any literature has assessed the change over time of economic evaluations in local-language journals, which would provide an additional signal of the state of economic capacity in LMIC regions.

2. The authors have a rich longitudinal database that could be further analyzed to assess such questions as how changes in the funding sources or disease patterns over time affect the number of cost per QALY or cost per DALY studies. Looking specifically at the cost per DALY numbers over time, how does one understand the growth in study numbers? Is it strongly correlated with growth in global health funding? (I would guess so), and are numbers of disease-specific studies correlated with change in disease burden? (I would guess not). The authors could show rates of growth year by year which would make comparisons across years and types of studies easier.

3. The metric of "under-" and "over-" studied as determined by the DALY burden is also
interesting and mostly unsurprising. Perhaps more could be said about the countries and sub-regions that show up green on both maps - such as North Africa, Middle East, and parts of Latin America. Those are the regions truly deficient in economic evaluations. Another point about the literature coverage relative to disease burden is to consider the demographics of the respective Super Regions. Since sub-Saharan Africa and South Asia have younger populations, they also merit more analysis of childhood conditions. If an age-specific disease burden measure were used as the scalar, would the conclusions about "over-" and "under-" studied be the same?

4. Like other reviewers, I find some issue with the statement about "historic proclivities" driving the choice between cost per QALY and cost per DALY, but for a different reason. The methodological underpinnings of the two measures require different types of data, some of which is culturally or contextually determined. Measuring disease prevalence is more straightforward - albeit not simple - than measuring attributes and states of health, and therefore more readily available in countries with limited data capacity; thus creating the means to produce more cost per DALY studies.

**Is the work clearly and accurately presented and does it cite the current literature?**
Yes

**Is the study design appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**
Yes

**Are all the source data underlying the results available to ensure full reproducibility?**
Yes

**Are the conclusions drawn adequately supported by the results?**
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Non-communicable disease economic evaluation

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

**Author Response 27 Feb 2018**

**Peter Neumann**, Tufts Medical Center, Boston, USA

**Comments from Rachel Nugent**, RTI International, Seattle, WA, USA; Department of
Comment #1. The authors have provided a useful summary of the up-to-date contents of the Tufts Medical Center CEA Registry and Global Health CEA Registry, which they manage. In particular, they contrast the contents of the two databases in regard to number of studies, geographic, disease burden, and disease-specific content. This provides a useful - if somewhat simplistic - overview of the availability and contents of current CEA studies. A few comments regarding the results as presented are provided below, along with a few suggestions about additional ways to interrogate the databases.

I am interested to see the time series of cost per QALY and cost per DALY studies presented in Figure 1. There is nothing especially surprising here for anyone working in the field, and it is heartening to see the steady increase in economic evaluations for health. I would appreciate the authors highlighting a few aspects of the databases that help one interpret the data. The methods clearly state that the databases draw from English-language articles indexed in PubMed, but it would be worth underscoring that selection creates a downward bias on the true number of cost per DALY studies. It would be very interesting to know if any literature has assessed the change over time of economic evaluations in local-language journals, which would provide an additional signal of the state of economic capacity in LMIC regions.

Response:
We have added the following text to a new limitations section of the Discussion:
...the databases we used are restricted to English-language articles indexed in PubMed. This restriction may have depressed the number of cost-per-DALY studies we identified to a greater extent proportionally than it may have depressed the number of cost-per-QALY studies we identified because a smaller proportion of the cost-per-DALY literature focuses on English-speaking countries.

Comment #2. The authors have a rich longitudinal database that could be further analyzed to assess such questions as how changes in the funding sources or disease patterns over time affect the number of cost per QALY or cost per DALY studies. Looking specifically at the cost per DALY numbers over time, how does one understand the growth in study numbers? Is it strongly correlated with growth in global health funding? (I would guess so), and are numbers of disease-specific studies correlated with change in disease burden? (I would guess not). The authors could show rates of growth year by year which would make comparisons across years and types of studies easier.

Response:
These are interesting questions, although we believe they go beyond the scope of what we set out to address. We have added text to the Discussion section of the paper to note areas for future research, including trends in the CEA literature in terms of diseases and geographic regions covered, funding patterns among donor organizations, and whether published studies correspond to society's most pressing needs.

Comment #3. The metric of "under-" and "over-" studied as determined by the DALY burden is also interesting and mostly unsurprising. Perhaps more could be said about the
countries and sub-regions that show up green on both maps - such as North Africa, Middle East, and parts of Latin America. Those are the regions truly deficient in economic evaluations. Another point about the literature coverage relative to disease burden is to consider the demographics of the respective Super Regions. Since sub-Saharan Africa and South Asia have younger populations, they also merit more analysis of childhood conditions. If an age-specific disease burden measure were used as the scalar, would the conclusions about "over-" and "under-" studied be the same?

Response:
These points are likewise interesting. We defer to future researchers to organize the data as needed and conduct these analyses.

Comment 4. Like other reviewers, I find some issue with the statement about "historic proclivities" driving the choice between cost per QALY and cost per DALY, but for a different reason. The methodological underpinnings of the two measures require different types of data, some of which is culturally or contextually determined. readily available in countries with limited data capacity; thus creating the means to produce more cost per DALY studies.

Response:
We have added text offering further explanation for the discrepancy between use of QALYs and DALYs by country wealth level (see response to Comment #1 from Michael Drummond).

Competing Interests: No competing interests were disclosed.
We would challenge the classification of pharmaceuticals as “tertiary prevention/treatment”. According to WHO, pharmaceuticals make up the bulk of OOP spending in most LICs (~77% based on the 2011 World Medicines Situation) and given fees, access and availability of facilities, self-medication is a major component of healthcare systems in LICs and LMICs.

We were surprised almost half of the DALY studies have received government funding. Is it possible to tell whether this is national governments of LICs and LMICs or donor governments? Given DALYs are mostly used in LICs and LMICs, are the governments of these countries commissioning this work? According to another study which we believe is worth citing, BMGF seems to be the single most commonly cited funder of DALY studies in LMICs. Our analysis as part of this paper (unpublished data) found that LIC government funded studies in malaria, TB and HIV studies (using DALYs (mostly) as an outcome measure), made up only 13%, 5% and 7% of the total in each disease area, respectively. Perhaps a more nuanced (eg broken down by decision maker global and domestic) analysis of funding source may reveal important messages assuming the data are available? Such a study would supplement nicely the PLoS paper cited earlier.

Though probably not for this paper, perhaps a discussion as to why the discrepancy between QALYs and DALYs by wealth level and what the message may be for transitioning countries, is warranted. So the database could be expanded perhaps in the future to include data on the country of origin of authors, which would in turn allow capturing a likely (but unproven) trend from poorer countries where publications come from mostly western authors funded by foreign donor foundations or governments, focus on MDGs and using DALYs to MICs/HICs where local authors funded by local money dominate, and with the focus shifting to NCDS and the use of QALYs. Such an analysis, if it confirms our hypothesis (and there are plenty of anecdotes from countries like the Philippines, China, Thailand, Brazil, Mexico and South Africa where national reference cases use QALYs as the outcome measure of preference), could then help reflect on what this might mean for countries in transition and the type of data and capacity they need to support their transition.

Figure 1 is useful, but it would be helpful to show the time trends not just in the counts of the papers but in the composition of papers by GBD category and super-region, as well as intervention. A more developed Figure 1 would set up nicely a discussion of what the future might hold and which we touch on earlier in our discussion regarding transition.

One of us (AM) has downloaded the cost/QALY data set to take a look and found that for 5895 out of 6438 records the field for publication year is blank. This info is needed to generate Figure 1 and so it should be there. It considerably lowers confidence in the integrity of the analysis when one discovers these things within a few seconds of downloading the database.

Figure 4 is also very useful but why not show similar analysis for the other GBD regions? Why so few regions? In an increasingly multipolar world it seems highly appropriate to conclude that research priorities in each region should be different. If one could generate graphs for all the GBD regions that would strengthen that case and give a sense of the extent of global diversity.
The authors write: “The contrast seems to reflect the historical proclivities rather than any inherent advantages for one metric’s use for a particular category of countries” – what might such “inherent advantages” be or indeed the historical proclivities (might the funding source have a role to play given the preference by BMGF a major funder of this work, for DALYs - https://beta.nice.org.uk/Media/Default/About/what-we-do/NICE-International/projects/MEEP-report.pdf)? Why not standardise on the QALY as both the methodological (see Airoldi and Morton²) and empirical foundations of the method are more well-established and there is evidence that when domestic payers make investment decisions in HICs and UMICs, QALY is their preferred outcome?

The findings relating to under-and over-studied conditions seem to us to be very interesting and relevant (perhaps more so than the QALY/DALY debate). Could the paper be retitled and/or the abstract rewritten to give these findings more prominence?

References
1. Santatiwongchai B, Chantarastapornchit V, Wilkinson T, Thiboonboon K, et al.: Methodological variation in economic evaluations conducted in low- and middle-income countries: information for reference case development. *PLoS One*. 2015; 10 (5): e0123853 PubMed Abstract | Publisher Full Text
2. Airoldi M, Morton A: Adjusting life for quality or disability: stylistic difference or substantial dispute?. *Health Econ*. 2009; 18 (11): 1237-47 PubMed Abstract | Publisher Full Text

Is the work clearly and accurately presented and does it cite the current literature?
Partly

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Partly

**Competing Interests**: No competing interests were disclosed.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
Peter Neumann, Tufts Medical Center, Boston, USA

Comments from Kalipso Chalkidou, Center for Global Development, London, UK.
Alec Morton, Department of Management Science, University of Strathclyde, Glasgow, UK.

Approved

Comment #1. This is a useful and timely study presenting informative analyses of the cost-per-QALY gained and cost-per-DALY averted literatures, relating them to geographical regions and to diseases and conditions prominent in these regions, as well as to wealth levels, types of intervention assessed and funding source. The authors draw conclusions as to the respective literatures’ evolution over the years and to things such as how well these link to disease burdens in their respective geographies.

Response:
No response needed.

Comment #2. We would challenge the classification of pharmaceuticals as “tertiary prevention/treatment”. According to WHO, pharmaceuticals make up the bulk of OOP spending in most LICs (~77% based on the 2011 World Medicines Situation) and given fees, access and availability of facilities, self-medication is a major component of healthcare systems in LICs and LMICs.

Response:
Note that we make no assumptions about an intervention's prevention stage based on its type. For example, we do not assume that pharmaceuticals are tertiary treatments. Instead, we assign the prevention level based on how the article describes the disease and the treatment.

While we had intended the original text to provide examples of typical primary and tertiary treatments, we see that the presentation of the results may have been confusing. We have therefore eliminated those examples and just report the overall proportion of articles in two categories. The text now reads:

Tertiary prevention (treatment) dominates the cost-per-QALY registry (62%), whereas the cost-per-DALY registry focuses far more on primary prevention (59%).

Comment #3a. We were surprised almost half of the DALY studies have received government funding. Is it possible to tell whether this is national governments of LICs and LMICs or donor governments? Given DALYs are mostly used in LICs and LMICs, are the governments of these countries commissioning this work? According to another study which we believe is worth citing1, BMGF seems to be the single most commonly cited funder of DALY studies in LMICs. Our analysis as part of this paper (unpublished data) found that LIC government funded studies in malaria, TB and HIV studies (using DALYs (mostly) as an outcome measure), made up only 13%, 5% and 7% of the total in each disease area, respectively. Perhaps a more nuanced (eg broken down by decision maker global and domestic) analysis of funding source may reveal important messages assuming...
the data are available? Such a study would supplement nicely the PLoS paper cited earlier.

Response:
We do not have the information needed to assess whether the governments of these countries are commissioning the work. The final paragraph of the Discussion now cites both papers identified by the reviewer and notes the need for further research on this and on other issues.

Comment #3b. Though probably not for this paper, perhaps a discussion as to why the discrepancy between QALYs and DALYs by wealth level and what the message may be for transitioning countries, is warranted. So the database could be expanded perhaps in the future to include data on the country of origin of authors, which would in turn allow capturing a likely (but unproven) trend from poorer countries where publications come from mostly western authors funded by foreign donor foundations or governments, focus on MDGs and using DALYs to MICs/HICs where local authors funded by local money dominate, and with the focus shifting to NCDS and the use of QALYs. Such an analysis, if it confirms our hypothesis (and there are plenty of anecdotes from countries like the Philippines, China, Thailand, Brazil, Mexico and South Africa where national reference cases use QALYs as the outcome measure of preference), could then help reflect on what this might mean for countries in transition and the type of data and capacity they need to support their transition.

Response:
We have added text offering further explanation for the discrepancy between use of QALYs and DALYs by country wealth level (see response to Comment #1 from Michael Drummond) and on the need for further research in this area.

Comment #4. Figure 1 is useful, but it would be helpful to show the time trends not just in the counts of the papers but in the composition of papers by GBD category and super-region, as well as intervention. A more developed Figure 1 would set up nicely a discussion of what the future might hold and which we touch on earlier in our discussion regarding transition.

Response:
We appreciate that providing time trends for other study characteristics, including GBD and super-region would be useful and could provide insight regarding the direction of the literature. In the revised paper, we have noted that as an area for future research and believe that as the cost-per-DALY literature in particular increases in size, the inferences that can be drawn will increase.

Comment #5. One of us (AM) has downloaded the cost/QALY data set to take a look and found that for 5895 out of 6438 records the field for publication year is blank. This info is needed to generate Figure 1 and so it should be there. It considerably lowers confidence in the integrity of the analysis when one discovers these things within a few seconds of downloading the database.

Response:
We very much appreciate the reviewers pointing out errors in our data extract. In response, we have regenerated the data extract, this time doing so by implementing all steps in a computer program to reduce the risk of introducing errors through manual manipulation of the original data. We are posting the computer program (written in STATA) and the extracted data. We have checked the distributions of the extracted data to make sure they appear to be reasonable.

Note that because we used the original dataset for our statistical analysis in version #1 of this paper, the errors in the extract did not affect the results.

Comment #6. Figure 4 is also very useful but why not show similar analysis for the other GBD regions? Why so few regions? In an increasingly multipolar world it seems highly appropriate to conclude that research priorities in each region should be different. If one could generate graphs for all the GBD regions that would strengthen that case and give a sense of the extent of global diversity.

Response:
We have chosen to include figures for only the three regions with the largest number of studies. But to address the reviewer's comment, we have also added a table that reports the standardized residual for each disease in each super region, relative to the regression line. We also report the mean and median residual for each disease (across all seven super regions) to characterize which diseases tend to be over- and under-studied in general.

Comment #7. The authors write: “The contrast seems to reflect the historical proclivities rather than any inherent advantages for one metric's use for a particular category of countries” – what might such “inherent advantages” be or indeed the historical proclivities (might the funding source have a role to play given the preference by BMGF a major funder of this work, for DALYs - https://beta.nice.org.uk/Media/Default/About/what-we-do/NICE-International/projects/MEEP-report.pdf)? Why not standardise on the QALY as both the methodological (see Airoldi and Morton2) and empirical foundations of the method are more well-established and there is evidence that when domestic payers make investment decisions in HICs and UMICs, QALY is their preferred outcome?

Response:
Making recommendations as to what measure the field should use is beyond the scope of this paper. We do, however, provide expanded text in an effort to explain why these measures are each used, and why the QALY measure is used more in high-income countries, and the DALY measure more in lower- and middle-income countries. See response to Comment #1 from Michael Drummond.

Comment #8. The findings relating to under-and over-studied conditions seem to us to be very interesting and relevant (perhaps more so than the QALY/DALY debate). Could the paper be retitled and/or the abstract rewritten to give these findings more prominence?

Response:
As this paper is the first comprehensive effort to describe the cost-per-DALY literature and compare it to the cost-per-QALY literature, we prefer to stick with emphasizing this aspect.
Neumann et al. examine the literature on economic evaluation through 2016, focusing specifically on studies measuring the health benefits in quality-adjusted life-years (QALYs) and disability-adjusted life-years (DALYs). A number of the findings of their research are as expected. First, cost per QALY studies have tended to focus on upper-middle and high-income countries, whereas cost per DALY studies have tended to focus on low and lower-middle income countries. This is likely to reflect the greater availability of preference values for health states in higher income countries and the preference of international donors, such as WHO and the World Bank, for studies estimating DALYs in lower income countries. Secondly, while the literature in both cost per QALY and cost per DALY studies is growing over time, there are more than 10 times the number of studies using QALYs than those using DALYs. This is likely to reflect the higher number of economist researchers and greater availability of funding for studies in high-income countries.

However, another finding of the research is not so easily explained. While the focus on topics for research, tertiary prevention (treatment) for studies using QALYs and primary prevention for studies using DALYs, it is surprising that the literature coverage is not closely aligned to disease burden in either high income or low income countries. Neumann et al. suggest that ‘the most commonly studied diseases, regions and interventions may reflect the financial interests of the CEA funders’. One can see why this might be the case in higher income countries, where many studies are funded by pharmaceutical countries, but it’s not clear why international donors might be favouring some diseases over others in lower income countries.

The analysis by Neumann et al. cannot directly answer that question, but one important factor driving economic evaluation in all countries is the number of promising interventions or programmes to evaluate. In this sense, the literature on economic evaluation mostly follows the priorities for research of technology manufacturers or public health specialists. For example, in recent years the research priorities of pharmaceutical companies in higher income countries have focused on specialty drugs for diseases such as cancer. This could be driven by discoveries in basic research or the pursuit of profits, or both. However, in all countries one might expect priorities for research to be driven not by the absolute level of disease burden, but the potential for modifying that burden through the development and implementation of health care treatments and
programmes.

One final issue touched on in the paper by Neumann et al. concerns the analytic choice between QALYs and DALYs in conducting economic evaluations. In commenting on the contrast in approach between higher and lower income countries, the authors state that ‘this contrast seems to reflect the historic proclivities of health economist researchers, rather than any inherent advantages for one metric's use for a particular category of countries’. In my view this issue deserves much deeper investigation.

In many lower income countries, health economist researchers may not have a realistic choice of approach, as QALYs may not exist for the country concerned. But which approach should the analyst use in a country for which both QALYs and DALYs are available? Comparisons between QALYs and DALYs and the implications for health policy decisions have been discussed in the papers by Airoldi and Morton (2009)\(^1\) and Robberstad (2005)\(^2\), with the conclusion that different decisions might be reached.

Although there are some minor differences in the theoretical constructs of QALYs and DALYs, two practical issues may be critical to the choice of approach. On the one hand QALYs are likely to be more ‘bespoke’ to the country where the study is being conducted and are more likely to reflect the health state preferences in the country concerned. However, on the other hand there is considerable variability in the methods used to elicit the preferences for health states in QALYs, which may threaten any standardized approach to decision-making. This issue has been recognized by the National Institute for Health and Care Excellence (NICE) in the United Kingdom, which, while recommending the use of QALYs, specifies the characteristics of the instrument that should be used to estimate them (NICE, 2013). By an extension of the same argument, an international donor requiring some standardization of approach to evaluation across several countries is likely to recommend the use of DALYs.

I answered 'Partly' to the question "Are sufficient details of methods and analysis provided to allow replication by others?" as access to the databases would be required for full replication.

**References**
1. Airoldi M, Morton A: Adjusting life for quality or disability: stylistic difference or substantial dispute?. *Health Econ* 2009; 18 (11): 1237-47 [PubMed Abstract](https://pubmed.ncbi.nlm.nih.gov/19972480/) | [Publisher Full Text](https://doi.org/10.1002/hec.1517)
2. Robberstad B: QALYs vs DALYs vs LYs gained: What are the differences, and what difference do they make for health care priority setting?. *Norsk Epidemiologi* 2009; 15 (2). [Publisher Full Text](https://doi.org/10.4085/1128-1347-15-02-0001)

**Is the work clearly and accurately presented and does it cite the current literature?**
Yes

**Is the study design appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Partly

**If applicable, is the statistical analysis and its interpretation appropriate?**
I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

**Author Response 27 Feb 2018**

**Peter Neumann,** Tufts Medical Center, Boston, USA

**Comments from Michael Drummond,** Centre for Health Economics, University of York, York, UK

**Approved**

Comment #1. Neumann et al. examine the literature on economic evaluation through 2016, focusing specifically on studies measuring the health benefits in quality-adjusted life-years (QALYs) and disability-adjusted life-years (DALYs). A number of the findings of their research are as expected. First, cost per QALY studies have tended to focus of upper-middle and high-income countries, whereas cost per DALY studies have tended to focus on low and lower-middle income countries. This is likely to reflect the greater availability of preference values for health states in higher income countries and the preference of international donors, such as WHO and the World Bank, for studies estimating DALYs in lower income countries. Secondly, while the literature in both cost per QALY and cost per DALY studies is growing over time, there are more than 10 times the number of studies using QALYs than those using DALYs. This is likely to reflect the higher number of economist researchers and greater availability of funding for studies in high-income countries.

Response:

We agree with the reviewer comments and have revised the Discussion to incorporate these points. We have added the following text to the Discussion:

Several factors may explain why cost-per-QALY studies predominate in high-income countries, while cost-per-DALY studies are more popular in lower and middle-income countries. The differences could, for example, reflect the availability of health utility weights in high-income countries and the lack of such information in lower-income settings. Researchers conducting CEA in countries with limited data capacity may find it easier and less expensive to use the cost-per-DALY metric.

The differences could also reflect the preferences and traditions of organizations that fund CEA studies. Foundations funding global health research may prefer the DALY metric, given the historic use of DALYs to measure global disease burden. In contrast, health authorities in high-income countries (e.g., the National Institute for Health and Care Excellence (NICE) in the United
Kingdom) have tended to recommend the use of QALYs in CEAs. The geographic differences between the cost-per-QALY and cost-per-DALY literature deserve further investigation, as our effort did not gather information on why authors used these measures.

Comment #2. However, another finding of the research is not so easily explained. While the focus on topics for research, tertiary prevention (treatment) for studies using QALYs and primary prevention for studies using DALYs, it is surprising that the literature coverage is not closely aligned to disease burden in either high income or low income countries. Neumann et al. suggest that ‘the most commonly studied diseases, regions and interventions may reflect the financial interests of the CEA funders’. One can see why this might be the case in higher income countries, where many studies are funded by pharmaceutical countries, but it’s not clear why international donors might be favouring some diseases over others in lower income countries.

Response:
We agree with the reviewer and have added the following paragraph to the Discussion: There is no clear explanation for these inconsistencies. As we have noted elsewhere, decisions to fund or conduct economic evaluations reflect not just the disease burden imposed by the targeted condition, but also the number of promising interventions or programs 19, 20. Because specialty drugs for diseases such as cancer represent important new interventions in high-income countries, and because pharmaceutical companies have the resources and incentive to characterize value for those interventions, much of the cost-per-QALY literature has recently focused on specialty drug therapies. These financial incentives are less pronounced in the lower- and middle-income countries that are much more the focus of the cost-per-DALY literature. In addition to disease burden, priorities in the cost-per-DALY literature may reflect the visibility and emotional salience of diseases, the influence of advocacy groups, the vagaries of reimbursement decisions19, and institutional priorities of the organizations sponsoring the research.

Comment #3. The analysis by Neumann et al. cannot directly answer that question, but one important factor driving economic evaluation in all countries is the number of promising interventions or programmes to evaluate. In this sense, the literature on economic evaluation mostly follows the priorities for research of technology manufacturers or public health specialists. For example, in recent years the research priorities of pharmaceutical companies in higher income countries have focused on specialty drugs for diseases such as cancer. This could be driven by discoveries in basic research or the pursuit of profits, or both. However, in all countries one might expect priorities for research to be driven not by the absolute level of disease burden, but the potential for modifying that burden through the development and implementation of health care treatments and programmes.

Response:
See response to Comment #3.

Comment #4. One final issue touched on in the paper by Neumann et al. concerns the analytic choice between QALYs and DALYs in conducting economic evaluations. In commenting on the contrast in approach between higher and lower income countries, the authors state that ‘this contrast seems to reflect the historic proclivities of health
economist researchers, rather than any inherent advantages for one metric's use for a particular category of countries'. In my view this issue deserves much deeper investigation.

In many lower income countries, health economist researchers may not have a realistic choice of approach, as QALYs may not exist for the country concerned. But which approach should the analyst use in a country for which both QALYs and DALYs are available? Comparisons between QALYs and DALYs and the implications for health policy decisions have been discussed in the papers by Airoldi and Morton (2009) and Robberstad (2005), with the conclusion that different decisions might be reached.

Although there are some minor differences in the theoretical constructs of QALYs and DALYs, two practical issues may be critical to the choice of approach. On the one hand QALYs are likely to be more 'bespoke' to the country where the study is being conducted and are more likely to reflect the health state preferences in the country concerned. However, on the other hand there is considerable variability in the methods used to elicit the preferences for health states in QALYs, which may threaten any standardized approach to decision-making. This issue has been recognized by the National Institute for Health and Care Excellence (NICE) in the United Kingdom, which, while recommending the use of QALYs, specifies the characteristics of the instrument that should be used to estimate them (NICE, 2013). By an extension of the same argument, an international donor requiring some standardization of approach to evaluation across several countries is likely to recommend the use of DALYs.

Response:
See response to Comment #1.

Comment #5. I answered 'Partly' to the question "Are sufficient details of methods and analysis provided to allow replication by others?" as access to the databases would be required for full replication.

Response:
We have made all data used in the analysis available, along with the computer code used for analyses and to create tables and figures.

Competing Interests: No competing interests were disclosed.